Literature DB >> 36268243

Stereotactic body radiation therapy and radiofrequency ablation in patients with hepatocellular carcinoma: not a rival but a partner for the cure.

Nalee Kim1, Jinsil Seong2.   

Abstract

Entities:  

Year:  2022        PMID： 36268243      PMCID： PMC9577995          DOI： 10.21037/hbsn-22-330

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  10 in total

1.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

2.  Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis.

Authors:  Koji Hara; Atsuya Takeda; Yuichiro Tsurugai; Yusuke Saigusa; Naoko Sanuki; Takahisa Eriguchi; Shin Maeda; Katsuaki Tanaka; Kazushi Numata
Journal:  Hepatology       Date:  2019-05-02       Impact factor: 17.425

3.  Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.

Authors:  Nalee Kim; Jason Cheng; Inkyung Jung; Ja Der Liang; Yu Lueng Shih; Wen-Yen Huang; Tomoki Kimura; Victor H F Lee; Zhao Chong Zeng; Ren Zhenggan; Chul Seung Kay; Seok Jae Heo; Jong Yoon Won; Jinsil Seong
Journal:  J Hepatol       Date:  2020-03-10       Impact factor: 25.083

4.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

5.  Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.

Authors:  Nalee Kim; Hyun Ju Kim; Jong Yun Won; Do Young Kim; Kwang-Hyub Han; Inkyung Jung; Jinsil Seong
Journal:  Radiother Oncol       Date:  2018-12-31       Impact factor: 6.280

6.  Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.

Authors:  Devalkumar J Rajyaguru; Andrew J Borgert; Angela L Smith; Reggie M Thomes; Patrick D Conway; Thorvardur R Halfdanarson; Mark J Truty; A Nicholas Kurup; Ronald S Go
Journal:  J Clin Oncol       Date:  2018-01-12       Impact factor: 44.544

7.  Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jiawei Hong; Linping Cao; Haiyang Xie; Yuanxing Liu; Jun Yu; Shusen Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 8.265

8.  Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study.

Authors:  Nalee Kim; Jason Cheng; Wen-Yen Huang; Tomoki Kimura; Zhao Chong Zeng; Victor H F Lee; Chul Seung Kay; Jinsil Seong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-20       Impact factor: 7.038

9.  Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.

Authors:  Tae Hyun Kim; Young Hwan Koh; Bo Hyun Kim; Min Ju Kim; Ju Hee Lee; Boram Park; Joong-Won Park
Journal:  J Hepatol       Date:  2020-10-05       Impact factor: 25.083

10.  Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study.

Authors:  Yang-Xun Pan; Mian Xi; Yi-Zhen Fu; Dan-Dan Hu; Jun-Cheng Wang; Shi-Liang Liu; Jin-Bin Chen; Li Xu; Zhong-Guo Zhou; Meng-Zhong Liu; Min-Shan Chen; Lei Zhao; Yao-Jun Zhang
Journal:  Cancers (Basel)       Date:  2019-08-05       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.